BioCentury | Nov 9, 2018
Company News

NICE recommends Jazz's Vyxeos for AML

The U.K.'s NICE issued a final appraisal determination (FAD) recommending Vyxeos daunorubicin/cytarabine to treat adults with newly diagnosed therapy-related acute myelogenous leukemia (AML) or AML with myelodysplasia-related changes. Vyxeos is a liposomal formulation of daunorubicin...
BioCentury | Sep 14, 2018
Company News

MS Society protests NICE rejection of Ocrevus for primary progressive MS

The U.K.'s NICE issued a final appraisal determination (FAD) on Sept. 10 recommending against the use of Ocrevus ocrelizumab from Roche (SIX:ROG; OTCQX:RHHBY) to treat primary progressive multiple sclerosis with imaging features characteristic of inflammatory...
BioCentury | Sep 10, 2018
Company News

MS Society protests NICE rejection of Ocrevus for primary progressive MS

The U.K.'s NICE issued a final appraisal determination (FAD) Sunday recommending against the use of Ocrevus ocrelizumab from Roche (SIX:ROG; OTCQX:RHHBY) to treat primary progressive multiple sclerosis with imaging features characteristic of inflammatory activity in...
BioCentury | Jul 13, 2018
Company News

NICE does not recommend Roche's ocrelizumab for primary progressive MS

The U.K.'s NICE said in an appraisal consultation it does not recommend the use of Ocrevus ocrelizumab from Roche (SIX:ROG; OTCQX:RHHBY) to treat primary progressive multiple sclerosis (MS) with imaging features characteristic of inflammatory activity...
BioCentury | Jun 22, 2018
Company News

NICE recommends Roche's Ocrevus for relapse-remitting multiple sclerosis

The U.K.'s NICE issued a final appraisal determination (FAD) recommending the use of Ocrevus ocrelizumab from Roche (SIX:ROG; OTCQX:RHHBY) to treat relapse-remitting multiple sclerosis. In January, the European Commission approved the second-generation humanized mAb against...
BioCentury | Jun 15, 2018
Company News

Zejula included on CDF

The U.K.'s NICE issued a final appraisal determination (FAD) recommending the use of Zejula niraparib from Tesaro Inc. (NASDAQ:TSRO) within the country's Cancer Drugs Fund (CDF) to treat relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian...
BioCentury | Jan 19, 2018
Company News

NICE FAD recommends J&J's Darzalex through CDF

The U.K.'s NICE issued a final appraisal determination (FAD) recommending that Darzalex daratumumab from Johnson & Johnson (NYSE:JNJ) be covered by the country's Cancer Drugs Fund as monotherapy to treat fourth-line relapsed and refractory multiple...
BioCentury | Dec 15, 2017
Company News

NICE recommends J&J's Imbruvica in MCL subgroup

The U.K.'s NICE issued a final appraisal determination (FAD) recommending the use of Imbruvica ibrutinib from Johnson & Johnson (NYSE:JNJ) to treat mantle cell lymphoma (MCL) in patients who have had only one prior line...
BioCentury | Oct 20, 2017
Company News

NICE adds Opdivo to CDF for head and neck cancer

The U.K.’s NICE said Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY) will be available on the country’s Cancer Drugs Fund for patients with metastatic head and neck cancer who have not responded to chemotherapy within...
BioCentury | Sep 29, 2017
Company News

NICE backs Bayer's Eylea

The U.K.’s NICE completed its first appraisal under its new fast track pathway, recommending the use of Eylea aflibercept from Bayer AG (Xetra:BAYN) to treat visual impairment due to choroidal neovascularization (CNV) in adults. The...
Items per page:
1 - 10 of 451